# Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease

> **NCT00206674** · PHASE3 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 286 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Sargramostim (Leukine)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00206674
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2006-06
- **Final completion:** 2006-06
- **Target enrollment:** 286 (ACTUAL)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00206674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00206674, "Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00206674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*